Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 31st total of 2,100,000 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 875,000 shares, the short-interest ratio is currently 2.5 days.

Institutional Trading of Compass Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the period. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Barclays PLC boosted its stake in shares of Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Compass Therapeutics by 3.1% during the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after purchasing an additional 3,822 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CMPX shares. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.80.

Compass Therapeutics Price Performance

Shares of CMPX opened at $3.22 on Monday. The firm has a market cap of $443.04 million, a P/E ratio of -8.70 and a beta of 0.92. The stock has a 50 day simple moving average of $1.90 and a two-hundred day simple moving average of $1.64. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $3.63.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, equities analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.